ArticleAlzheimer's research & therapy2018
Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.
Article in Alzheimer's research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- The full spectrum of ethical issues in dementia research: findings of a systematic qualitative review.BMC medical ethics · 2021Pooled it
- Pooled it
- Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline.Alzheimer's research & therapy · 2026Article
- Psychosocial implications of learning amyloid PET results in an observational cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024Article
- Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure.The journal of prevention of Alzheimer's disease · 2024Article
- A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.The journal of prevention of Alzheimer's disease · 2024Article
- The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants.The journal of prevention of Alzheimer's disease · 2024Observational
- Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- Disclosing Individual Results in Dementia Research: A Proposed Study Participant's Bill of Rights.Journal of Alzheimer's disease : JAD · 2022Article
- Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.Journal of the American Geriatrics Society · 2021Article
- Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?The journal of prevention of Alzheimer's disease · 2021Article
- Article
- Response to "Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure".Alzheimer's research & therapy · 2019Article
- Avoiding methodological bias in studies of amyloid imaging results disclosure.Alzheimer's research & therapy · 2019Article
- Short-term psychological impacts of Alzheimer's disease risk disclosure based on blood-biomarker results.Alzheimer's & dementia (New York, N. Y.)Article
- Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
backgroundThe experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer's disease (AD) into clinical practice.
methodsWe interviewed 33 persons whose "not elevated" brain amyloid imaging biomarker result made them ineligible for a preclinical AD trial.
resultsMost participants (n = 17) reported being informed that they did not demonstrate adequately elevated amyloid to qualify, whereas some (n = 14) reported being told they had no amyloid or plaques. Relief (n = 17) and disappointment related to not being able to participate (n = 12) were the most common reactions to results. Nearly all participants would have made healthy lifestyle changes if they had received an "elevated" result, would have another scan, and would participate in another AD prevention trial.
conclusionsAlthough some participants may misconstrue results, disclosure of a "not elevated" amyloid result in the research setting causes little behavior change; willingness to participate in AD research remains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.